
    
      This tiral adopts a multi-center, single-arm, multi-cohort, and open-label design to evaluate
      the efficacy and safety of keynatinib in patients with relapsed/refractory B-cell lymphoma.

      There will be three cohorts in this trial, details as follows: Cohort 1: R/R-PCNSL subjects;
      Cohort 2: R/R-CLL/SLL subjects; Cohort 3: R/R-MCL subjects.

      10-25 subjects will be enrolled in the R/R-PCNSL, R/R-CLL/SLL, and R/R-MCL cohorts,
      respectively.
    
  